Amphastar Pharmaceuticals (AMPH) Cost of Revenue (2013 - 2026)

Amphastar Pharmaceuticals' Cost of Revenue history runs 14 years deep, the most recent figure standing at $100.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 18.26% year-over-year to $100.8 million in Q1 2026; TTM through Mar 2026 was $379.4 million, a 4.91% increase from a year earlier, with the FY2025 full-year figure at $363.8 million, up 1.6% from the prior year.
• Cost of Revenue advanced to $100.8 million in Q1 2026 per AMPH's latest filing, from $97.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $100.8 million in Q1 2026 and bottomed at $60.1 million in Q2 2022.
• The 5-year median for Cost of Revenue is $82.0 million (2023), against an average of $80.4 million.
• Across the five-year window, Cost of Revenue grew 28.36% in 2023 and slipped 2.44% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $63.9 million in 2022, then grew by 28.36% to $82.0 million in 2023, then rose by 21.85% to $99.9 million in 2024, then slipped by 2.44% to $97.4 million in 2025, then grew by 3.5% to $100.8 million in 2026.
• Per Business Quant, the three latest AMPH Cost of Revenue figures stand at $100.8 million (Q1 2026), $97.4 million (Q4 2025), and $93.2 million (Q3 2025).